Quote:

---

Would it be fair to assume that means the largest drop off on the survival rate happens in that time frame for Trodelvy and LL provides a longer period of time before a drop off in survival rate?

---

Trodelvy has a 20% death rate vs. surviving patients starting at 3 months that accelerates a bit as time goes on up to 30 months with 2 patients surviving. With leronlimab we don't have that data. We do know that at 4 years overall survival was 17.8% and at 4 years and 4 months our survival rate was 14.2% with all survivors at that time having no evidence of cancer.